- Accession Number
Dimenhydrinate, also known as Dramamine or Gravol, is an over-the-counter drug used to prevent nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is a combination drug composed of Diphenhydramine and 8-chlorotheophylline in a salt form, with 53%-55.5% of diphenhydramine, and not less than 44%-47% of 8-chlorotheophylline, calculated on the dried basis.
The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system 3 while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade 4. The addition of 8-chlorotheophylline was initially intended to counteract the sedative effects of diphenhydramine.
When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation 2.
- Small Molecule
- Average: 469.97
- Chemical Formula
- (O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
- 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
- Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
- diphenhydramine 8-chlorotheophyllinate
- diphenhydramine 8-chlorotheophylline
- Diphenhydramine theoclate
- N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
- O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate
- β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.Learn More
Dimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.
- Mechanism of action
The mechanism by which some antihistamines exert their antiemetic, anti-motion sickness, and anti-vertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.
Target Actions Organism AHistamine H1 receptorantagonist Humans
Well absorbed after oral administration.
- Volume of distribution
- Not Available
- Protein binding
98 to 99%.
Hepatic (cytochrome P-450 system).
- Route of elimination
- Not Available
1 to 4 hours
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.Learn More
Symptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.
- Affected organisms
- Humans and other mammals
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Acebutolol The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Acebutolol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Dimenhydrinate. Acetophenazine The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Acetophenazine. Aclidinium Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Dimenhydrinate. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dimenhydrinate. Agomelatine The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Agomelatine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dimenhydrinate. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Dimenhydrinate. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dimenhydrinate.Additional Data Available
- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.Learn more
- SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.Learn more
- Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.Learn more
- ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.Learn more
- Food Interactions
- Avoid alcohol.
- Take with food.
Purchasing individual compounds or compound libraries for your research?Learn More
- Active Moieties
Name Kind UNII CAS InChI Key Diphenhydramine salt 8GTS82S83M 58-73-1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 8-chlorotheophylline salt GE2UA340FM 85-18-7 RYIGNEOBDRVTHA-UHFFFAOYSA-N
- Product Images
- International/Other Brands
- Gravol (Church & Dwight) / Vertirosan (Astellas) / Vomex A (Astellas) / Xamamina (Adilna)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dimenhydrinate Inj 10mg Liquid Intravenous Sandoz Canada Incorporated 1973-12-31 Not applicable Dimenhydrinate Inj 10mg/ml Liquid Intravenous Astra Pharma Inc. 1986-12-31 1999-07-29 Dimenhydrinate Inj 50mg USP Liquid Intramuscular; Intravenous Sandoz Canada Incorporated 1973-12-31 Not applicable Dimenhydrinate Injection 50mg/ml Solution Intramuscular; Intravenous Astra Zeneca 1986-12-31 2005-05-31 Dimenhydrinate Injection USP Solution Intramuscular; Intravenous Teligent Ou 2016-01-28 Not applicable Dimenhydrinate Injection USP 250mg/5ml (50mg/ml) Solution Intramuscular; Intravenous Teligent Ou 2008-06-26 Not applicable Dimenhydrinate Injection USP With Preservative Solution Intramuscular; Intravenous Teligent Ou 2016-01-28 Not applicable Dimenhydrinate Injection, USP Solution Intramuscular; Intravenous Mylan Pharmaceuticals 1994-12-31 Not applicable Gravol Im Solution Intramuscular Church & Dwight Canada Corp 1953-12-31 Not applicable Gravol IV Ampoules Solution Intravenous Church & Dwight Canada Corp 1953-12-31 2008-07-30Additional Data Available
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Dimenhydrinate Injection, solution 50 mg/1mL Intramuscular; Intravenous Fresenius Kabi USA, LLC 2004-11-29 Not applicableAdditional Data Available
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Airmit Ace Tablet 25 mg/1 Oral Sato Pharmaceutical Co., Ltd. 2005-03-11 Not applicable Anti-nauseant Tablet Oral Pharmascience Inc 2002-08-23 Not applicable Anti-nauseant Tablet Oral Apotex Corporation 2013-07-02 Not applicable Anti-nauseant Tablet Oral Vita Health Products Inc 2000-05-01 Not applicable Anti-nauseant Tablet Oral TEVA Canada Limited Not applicable Not applicable Anti-nauseant Tablet Oral Pharmascience Inc Not applicable Not applicable Anti-nauseant Liquid Gels Capsule Oral Vita Health Products Inc 2020-08-04 Not applicable Anti-nauseant Tablet Tablet Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1998-05-26 2008-08-07 Apo Dimenhydrinate Tab 50mg Tablet Oral Apotex Corporation 1977-12-31 Not applicable Children's Motion Sickness Liq Solution Oral Tanta Pharmaceuticals Inc 1996-12-31 2020-05-31Additional Data Available
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Gravergol Capsules Dimenhydrinate (50 mg) + Caffeine (100 mg) + Ergotamine tartrate (1 mg) Capsule Oral Can Med Pharma Inc. 1957-12-31 2011-12-07
- Drug Categories
- Autonomic Agents
- Benzene Derivatives
- Benzhydryl Compounds
- Central Nervous System Agents
- Central Nervous System Depressants
- Ethanolamine Derivatives
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Moderate Risk QTc-Prolonging Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Pharmaceutical Preparations
- QTc Prolonging Agents
- Not classified
- CAS number
- InChI Key
- IUPAC Name
- 8-chloro-1,3-dimethyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; [2-(diphenylmethoxy)ethyl]dimethylamine
- Synthesis Reference
Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
- General References
- Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T: Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl. 1993;501:10-5. [PubMed:8447218]
- Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]
- Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456]
- Spealman RD: Psychomotor stimulant effects of methylxanthines in squirrel monkeys: relation to adenosine antagonism. Psychopharmacology (Berl). 1988;95(1):19-24. [PubMed:3133696]
- AHFS Codes
- 56:22.08 — Antihistamines
- 04:04.04 — Ethanolamine Derivatives
- Download (72 KB)
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Post Operative Nausea and Vomiting (PONV) 1 4 Completed Treatment Gastroenteritis 1 4 Completed Treatment Nausea / Vertigo / Vomiting 1 4 Completed Treatment Vertigo, Peripheral 1 3 Unknown Status Treatment Vertigo, Peripheral 1 2 Completed Treatment Post Operative Nausea and Vomiting (PONV) 1 1 Completed Treatment Healthy Volunteers 1 Not Available Completed Treatment Nausea / Vomiting 1
- App pharmaceuticals llc
- Baxter healthcare corp anesthesia and critical care
- Watson laboratories inc
- Wyeth ayerst laboratories
- Alra laboratories inc
- Heather drug co inc
- Nexgen pharma inc
- APP Pharmaceuticals
- C.O. Truxton Inc.
- Consolidated Midland Corp.
- Dispensing Solutions
- Hospira Inc.
- Ivax Pharmaceuticals
- Major Pharmaceuticals
- Martin Surgical Supply
- Medisca Inc.
- Nexgen Pharma Inc.
- Pfizer Inc.
- Pharmacia Inc.
- Prescript Pharmaceuticals
- Southwood Pharmaceuticals
- Dosage Forms
Form Route Strength Tablet Oral 25 mg/1 Suspension Solution Oral Tablet, coated Oral 50 mg Capsule Oral 50 mg Tablet Oral 50 MG Injection, solution Intramuscular; Intravenous 50 mg/1mL Tablet Oral 50 mg/1 Tablet, film coated Oral 50 mg/1 Liquid Intravenous Liquid Intramuscular; Intravenous Solution Intramuscular; Intravenous Liquid Oral Tablet Oral Syrup Oral 15 mg/5mL Injection Intramuscular; Intravenous 50 mg/ml Tablet, chewable Oral 50 mg/1 Tablet, chewable Oral 25 mg/1 Syrup Oral 12. 5MG/5ML Capsule Oral Capsule, extended release Oral Solution Intramuscular Tablet, multilayer Oral Solution Intravenous Capsule Oral Tablet, extended release Oral Suppository Rectal Suppository Rectal 25 mg Tablet, chewable Oral Syrup Oral Tablet Oral 0.05 g Syrup Oral 1 5MG/5ML Tablet, coated Oral 50 mg/1 Syrup Oral 2 5MG/5ML Tablet, coated Oral 25 mg Gum, chewing Oral 20 MG Tablet, sugar coated Oral 20 mg Suppository Rectal 100 mg Suppository Rectal 50 mg Tablet, film coated Oral 50 mg Suppository Rectal 150 MG Tablet, sugar coated Oral 50 MG Suppository Rectal 70 MG Suppository Rectal 40 MG Tablet, orally disintegrating Sublingual 50 MG
Unit description Cost Unit Dimenhydrinate 50 mg/ml vial 5.7USD ml Dimenhydrinate I.M. 50 mg/ml 1.17USD ml Meclizine 12.5 mg tablet 0.62USD tablet Dramamine less drowsy tablet 0.42USD tablet Dimenhydrinate I.V. 10 mg/ml 0.32USD ml Dramamine 50 mg tablet 0.28USD tablet Novamine 15% iv solution 0.09USD ml Dimenhydrinate 100% powder 0.07USD g Driminate 50 mg tablet 0.05USD tablet Dimenhydrinate 50 mg tablet 0.03USD tabletDrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
- Not Available
- Experimental Properties
Property Value Source melting point (°C) 102.5-104 Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co. water solubility 3000 mg/L MERCK INDEX (1996); approx. logP -0.39 Not Available
- Predicted Properties
Property Value Source Water Solubility 9.86 mg/mL ALOGPS logP 0.44 ALOGPS logP 3.65 ChemAxon logS -1.3 ALOGPS pKa (Strongest Basic) 8.87 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 12.47 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 79.93 m3·mol-1 ChemAxon Polarizability 30.02 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon
- Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9975 Blood Brain Barrier + 0.8551 Caco-2 permeable + 0.5198 P-glycoprotein substrate Substrate 0.7863 P-glycoprotein inhibitor I Non-inhibitor 0.6923 P-glycoprotein inhibitor II Inhibitor 0.6502 Renal organic cation transporter Non-inhibitor 0.6507 CYP450 2C9 substrate Non-substrate 0.7536 CYP450 2D6 substrate Non-substrate 0.8181 CYP450 3A4 substrate Substrate 0.7086 CYP450 1A2 substrate Inhibitor 0.5287 CYP450 2C9 inhibitor Non-inhibitor 0.6308 CYP450 2D6 inhibitor Non-inhibitor 0.8589 CYP450 2C19 inhibitor Non-inhibitor 0.5817 CYP450 3A4 inhibitor Non-inhibitor 0.9028 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5738 Ames test Non AMES toxic 0.5629 Carcinogenicity Non-carcinogens 0.7548 Biodegradation Not ready biodegradable 0.8211 Rat acute toxicity 2.4087 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5364 hERG inhibition (predictor II) Inhibitor 0.5405
- Mass Spec (NIST)
- Not Available
- Not Available
- Pharmacological action
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- Uniprot ID
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
Drug created on June 13, 2005 07:24 / Updated on November 23, 2020 09:08